AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

The growing prevalence of COPD among women can be attributed to a combination of biological, environmental, and societal ...

Ensifentrine is a promising supplementary therapeutic option in the management of chronic obstructive pulmonary disease (COPD), according to systematic review and meta-analysis findings published in ...

Chronic obstructive pulmonary disease (COPD) market Insights: Rising prevalence of COPD due to aging and smoking.

The rise in lung-related disorders in India is exacerbated by air pollution, tobacco use, and traditional cooking methods.

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

What are the symptoms of emphysema? - Understanding the condition is the first step towards taking control of your lung ...

Multiple chemicals in cigarette smoke and e-cigarettes alter the function of a key type of lung immune cell. Cigarette ...

In their study, the researchers looked at the effects of cigarette smoke on Mucosal-Associated Invariant T (MAIT) cells, a ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

The following is a summary of “Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a ...